fda pulling semaglutide 🚨 Moves to Shut Down Mass-Market Compounded GLP-1s The FDA is taking action to restrict widely marketed, non–FDA-approved compounded GLP-1 products, citing concerns over safety, quality, and misleading claims. As demand Public Comment Closes on the

The most frequent complaints focus on shipping delays and fulfillment problems

Despite these promising advancements, significant challenges remain

boulardii, at 5 billion CFU (colony forming units) (Garcia-Collinot 2020)(Kwak 2014)(Liang 2016) 128 patients with gastrointestinal cancer and H-SIBO were treated with three strains of Bifidobacterium three times a day for four weeks

its about maintaining that result with grace, ease, and minimal emotional turbulence

Our secure platform lets you: Schedule same-day telehealth consults Request prescription refills online Get personalized care from home Your Health, On Your Schedule Online Appointments and Prescriptions Book virtual or in-person visits in minutesno waiting on hold